Table of Contents Author Guidelines Submit a Manuscript
Case Reports in Oncological Medicine
Volume 2011, Article ID 638794, 5 pages
http://dx.doi.org/10.1155/2011/638794
Case Report

18FDG-PET at 1-Month Intervals Is a Better Predictive Marker for GISTs That Are Difficult to Be Diagnosed Histopathologically: A Case Report

1Department of Clinical Oncology, Akita University Graduate School of Medicine, 1-1-1 Hondo, Akita 010-8543, Japan
2Division of Clinical Pathology, Faculty of Medicine, Akita University, 1-1-1 Hondo, Akita 010-8543, Japan
3Department of Gastroenterological Surgery, Akita University, 1-1-1 Hondo, Akita 010-8543, Japan
4Department of Gastroenterology and Neurology, Akita University, 1-1-1 Hondo, Akita 010-8543, Japan
5Department of Radiology, Akita University, 1-1-1 Hondo, Akita 010-8543, Japan

Received 3 July 2011; Accepted 3 August 2011

Academic Editors: S. B. Chichareon and A. Goodman

Copyright © 2011 Kazunori Otsuka et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. M. Stamatakos, E. Douzinas, C. Stefanaki et al., “Gastrointestinal stromal tumor,” World Journal of Surgical Oncology, vol. 7, article 1477, p. 61, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  2. D. A. Tuveson, N. A. Willis, T. Jacks et al., “STI571 inactivation of the gastrointestinal stromal tumor c-KIT oncoprotein: biological and clinical implications,” Oncogene, vol. 20, no. 36, pp. 5054–5058, 2001. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  3. C. L. Corless, J. A. Fletcher, and M. C. Heinrich, “Biology of gastrointestinal stromal tumors,” Journal of Clinical Oncology, vol. 22, no. 18, pp. 3813–3825, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  4. G. D. Demetri, M. Von Mehren, C. D. Blanke et al., “Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors,” The New England Journal of Medicine, vol. 347, no. 7, pp. 472–480, 2002. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  5. T. Caramella, S. Schmidt, P. Chevallier et al., “MR features of gastrointestinal stromal tumors,” Clinical Imaging, vol. 29, no. 4, pp. 251–254, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  6. M. Polkowski, W. Gerke, D. Jarosz et al., “Diagnostic yield and safety of endoscopic ultrasound-guided trucut [corrected] biopsy in patients with gastric submucosal tumors: a prospective study,” Endoscopy, vol. 41, no. 4, pp. 329–334, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  7. G. Antoch, J. Kanja, S. Bauer et al., “Comparison of PET, CT, and dual-modality PET/CT imaging for monitoring of imatinib (STI571) therapy in patients with gastrointestinal stromal tumors,” Journal of Nuclear Medicine, vol. 45, no. 3, pp. 357–365, 2004. View at Google Scholar · View at Scopus
  8. C. Sogawa, A. B. Tsuji, H. Sudo et al., “C-kit-targeted imaging of gastrointestinal stromal tumor using radiolabeled anti-c-kit monoclonal antibody in a mouse tumor model,” Nuclear Medicine and Biology, vol. 37, no. 2, pp. 179–187, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  9. C. E. Devine and O. Mawlawi, “Radiation safety with positron emission tomography and computed tomography,” Seminars in Ultrasound, CT and MRI, vol. 31, no. 1, pp. 39–45, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  10. B. L. Eisenberg, J. Harris, C. D. Blanke et al., “Phase II trial of neoadjuvant/adjuvant imatinib mesylate (IM) for advanced primary and metastatic/recurrent operable gastrointestinal stromal tumor (GIST): early results of RTOG 0132/ACRIN 6665,” Journal of Surgical Oncology, vol. 99, no. 1, pp. 42–47, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  11. M. von Mehren and J. C. Watson, “Perioperative tyrosine kinase inhibitors for GIST: standard or an idea that needs further investigation?” Oncology, vol. 23, no. 1, pp. 65–66, 2009. View at Google Scholar · View at Scopus
  12. J. Martin-Broto, A. Gutierrez, X. Garcia-del-Muro et al., “Prognostic time dependence of deletions affecting codons 557 and/or 558 of KIT gene for relapse-free survival (RFS) in localized GIST: a Spanish Group for Sarcoma Research (GEIS) Study,” Annals of Oncology, vol. 21, no. 7, pp. 1552–1557, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  13. J. Blay, N. Bin, P. A. Bui et al., “Correlation of the topography of KIT exon 11 mutation with primary GIST location and predictive value for PFS in patients with advanced GIST: results from the BFR14 andomized phase III trial of the French Sarcoma Group,” in Proceedings of the Annual Meeting of American Society of Clinical Oncology, (ASCO '10), Illinois, Ill, USA, June 2010, http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_meeting_categories_view&confID=74.